Takara Bio USA, Inc. (formerly Clontech Laboratories, Inc.), a wholly owned subsidiary of Takara Bio Inc., develops, manufactures, and distributes a wide range of life science research reagents under the Takara, Clontech, and Cellartis brands. To keep you up to date with the latest happenings at Takara Bio USA, we have compiled our recent announcements and press releases below.
Date: May 17, 2018
Mountain View, CA—May 17, 2018—The Takara Bio Group, the leading provider of human stem cell differentiation services globally, has launched the Cellartis Directed Differentiation to Beta Cells Service for the delivery of high-quality, custom human induced pluripotent stem cell (hiPSC)-derived beta cells for diabetes research and metabolic disease modeling.
SMARTer ICELL8 technology aids in single-nuclei sequencing of triple-negative breast cancer to uncover chemoresistance evolution
Date: May 8, 2018
Mountain View, CA—May 8, 2018—A recent study including single-cell transcriptome analysis has revealed an evolutionary model of chemoresistance in triple-negative breast cancer (TNBC) patients. This groundbreaking work, led by Professor Nicholas Navin (The University of Texas MD Anderson Cancer Center), was published in the May issue of Cell and utilized Takara Bio’s SMARTer ICELL8 single-cell automation platform.
Date: April 30, 2018
A leading biotechnology company has developed a rapid test to measure recombinant lentivirus titers using a smartphone as a diagnostic reader. Takara Bio USA, Inc. (TBUSA; formerly Clontech Laboratories, Inc.) teamed up with smartphone diagnostics specialists, Novarum DX, to develop an integrated, mobile platform which detects and quantifies recombinant lentivirus in packaging cell supernatants.
Takara Bio unveils a new open-platform single-cell automation system compatible with industry-leading SMART-Seq technology for sensitive full-length transcriptome analysis at AGBT 2018
Date: February 12, 2018
Mountain View, CA—February 12, 2018—To advance the understanding of cell diversity and how that diversity impacts complex cellular functions including interactions with other cells and molecules, growth, and disease states, Takara Bio USA, Inc., (TBUSA, formerly Clontech Laboratories, Inc.), a wholly owned subsidiary of Takara Bio Inc., is proud to announce the launch of the SMARTer ICELL8 cx System. The system will be presented to the scientific community at the Advances in Genome Biology and Technology (AGBT) General Meeting in Orlando FL, February 12–15, 2018.
Takara Bio USA, Inc., announces the use of the SMARTer ICELL8 Single-Cell System in clinical studies
Date: January 19, 2018
Mountain View, CA—January 19, 2018—Takara Bio USA, Inc., (TBUSA, formerly Clontech Laboratories, Inc.), a wholly owned subsidiary of Takara Bio Inc., is proud to announce that City of Hope has recently procured a SMARTer ICELL8 Single-Cell System to perform high-level studies involving high-throughput single-cell RNA-seq applications. This automated system provides a proven platform for unbiased isolation, evaluation, and selection of over a thousand single cells for downstream analyses, including next-generation sequencing (NGS), backed by recent citations in the literature.
Date: July 30, 2017
Rubicon Genomics and WaferGen Bio-systems are now members of the Takara Bio Group. Going forward, all orders, inquiries, and technical support requests involving Rubicon and WaferGen products should be submitted directly to Takara Bio USA, Inc. Click the link above for more details.
Date: March 1, 2017
Mountain View, CA—March 1, 2017—Takara Bio USA Holdings, Inc. ("TBUSH") announced that it has completed the acquisition of WaferGen Bio-systems, Inc. ("WaferGen"), WaferGen has become a wholly owned subsidiary of TBUSH as of February 28, 2017 (US local time).
Date: February 28, 2017
WaferGen Bio-systems, Inc., a biotechnology company that offers innovative genomic technology solutions for single-cell analysis and clinical research, is now a member of the Takara Bio Group.
Takara Bio USA, Inc. and TeselaGen Biotechnology, Inc. release a powerful new primer tool for easy design of In‑Fusion Cloning experiments
Date: January 24, 2017
Mountain View and San Francisco, CA—January 24, 2017—Takara Bio USA, Inc. (TBUSA, formerly Clontech Laboratories, Inc.), a wholly owned subsidiary of Takara Bio Inc., today announced the launch of the In-Fusion Cloning Primer Design Tool, powered by TeselaGen Biotechnology, Inc. software. In-Fusion Cloning, developed by TBUSA, is a unique method that seamlessly joins together linear fragments of DNA in a single, 15-minute reaction. The free, online primer design tool facilitates easy design and a smooth transition from planning to experimental work.
Takara Bio USA, Inc.
United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)1.3904.6880 • Japan: +81.(0)77.565.6999
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. © 2018 Takara Bio Inc. All Rights Reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at takarabio.com.